Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques

International Journal of Cancer

Volumn 113, Issue 1, 2005, Pages 88-92

  Jachimczak, Piotr ^a,d   Apfel, Rainer ^b   Bosserhoff, Anja Kathrin ^b   Fabel, Klaus ^b   Hau, Peter ^b   Tschertner, Ines ^b   Wise, Petra ^b   Schlingensiepen, Karl Hermann ^a   Schuler Thurner, Beatrix ^c   Bogdahn, Ulrich ^b  

^a Antisense Pharma GmbH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Antisense Pharma GmbH   (Germany)

Author keywords

Antisense; Immune escape; Integrins; Melanoma; MIA

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RECOMBINANT INTERLEUKIN 2; TUMOR PROTEIN;

ARTICLE; CANCER INHIBITION; CELL ACTIVITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MELANOMA CELL; MITOGENICITY; NUCLEIC ACID PROBE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATES; PROTEINS; RECOMBINANT PROTEINS; THIONUCLEOTIDES;

EID: 8644222129     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20549     Document Type: Article

References (24)

1. Smith C, Cerundolo V. Immunotherapy of melanoma. Review article. Immunology 2001;104:1-7.
2. Geertsen R, Hofbauer G, Kamarashev J, Yue FY, Dummer R. Immune escape mechanism in malignant melanoma (review). Int J Mol Med 1999;3:49-57.
3. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
4. Ravaud A, Legrand E, Delaunay MM, Bussieres E, Coulon V, Cany L, Huet S, Verdier D, Kind M, Chomy F, Bui BN, Gualde N. A phase I trial of repeated tumor infiltrating lymphocytes (TIL) infusion in metastatic melanoma. Br J Cancer 1995;71:331-6.
5. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effects of transferred R cells. PNAS 2002;99:16168-73.
6. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U. Cloning of a novel malignant melanoma-derived growth regulatory protein, MIA. Cancer Res 1994;54:5695-701.
7. Stoll R, Renner CH, Zweckstetter M, Brüggert M, Ambrosius D, Palme S, Engh RA, Golob M, Breibach I, Buettner R, Voelter W, Holak TA, et al. The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. EMBO J 2001;20:340-9.
8. Lougheed JC, Holton JM, Alber T, Bazan JF, Handel TM. Structure of melanoma inhibitory activity protein, a member of recently identified family of secreted proteins. PNAS 2001;98:5515-20.
9. Bosserhoff A-K, Stoll R, Sleeman JP, Bataille F, Buettner R, Holak TA. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest 2003;83:1583-94.
10. de Vries TJ, Fourkour A, Punt CJ, Diepstra H, Ruiter DJ, van Muijen GN. Melanoma-inhibiting activity (MIA)mRNA is not exclusively transcribed in melanoma cells: low levels of MIAmRNA are present in various cell types and in peripheral blood. Br J Cancer 1999;81:1066-77.
11. Bosserhoff AK, Lederer M, Kaufmann M, Hein R, Stolz W, Apfel R, Bogdahn U, Buettner R. MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res 1999;19:2691-3.
12. Bosserhoff AK, Hauschild A, Hein R, Schadendorf D, Stockflesh E, Bogenrieder T, Landthaler M, Buettner R, Stolz W. Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter Study. J Invest Dermatol 2000;114:395-6.
13. Bosserhoff AK, Echtenacher B, Hein R, Buettner R. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vitro. Melanoma Res 2001;11:417-21.
14. Shimizu Y, Newman W, Tanaka Y, Shaw S. Lymphocyte interactions with endothelial cells. Immunol Today 1992;13:106-12.
15. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
16. Donskov F, Basse PH, Hokland M. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. Nat Immun 1996;15:134-6.
17. Adams DH, Yannelli JR, Newman W, Lawley T, Ades E, Rosenberg SA, Shaw S. Adhesion of tumor-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis. Br J Cancer 1997;75:1421-31.
18. Rose DM, Grabovsky V, Alon R, Ginsberg MH. The affinity of integrin α4β1 governs lymphocyte migration. J Immunol 2001;167:2824-30.
19. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W. The effects of transforming growth factor β2-speciftc phosphorothioate antisense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993;78:944-51.
20. Lichtenfels R, Biddison WE, Schulz H, Vogt AB, Martin R. CARELASS (Calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods 1994;172:227-39.
21. Guba M, Bosserhoff AK, Steinbauer M, Abels C, Anthuber M, Buettner R, Jauch KW. Overexpression of Melanoma Inhibitory Activity (MIA) enhances extravasation and metastasis of A-Mel 3 melanoma cells in vivo. Br J Cancer 2000;83:1216-22.
22. Poser I, Golob M, Buettner R, Bosserhoff AK. Related upregulation of >HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003;23:2991-8.
23. Jachimczak P, Kempt P, Tschertner I, Jachnik B, Thurner B, Bogdahn U, Apfel R. Immunosuppressive effects of Melanoma-Inhibiting Activity (MIA) - a possible role in tumor-host interactions. Proc AACR 2000;115:A734.
24. Kennedy-Smith AG, McKenzie JL, Owen MC, Davidson PJT, Vuckovic S, Hart DNJ. Prostate Specific Antigen inhibits immune responses in vitro: a potential role in prostate cancer. J Urol 2002;168:741-7.